Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About ABT Interactive Breakdown Better Bets vs. ABT Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Abbott Laboratories (ABT)

Market Price (10/22/2025): $127.68 | Market Cap: $222.6 Bil
Sector: Health Care | Industry: Health Care Equipment

Abbott Laboratories (ABT)

Market Price (10/22/2025): $127.68
Market Cap: $222.6 Bil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.1%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.6%		 Weak multi-year price returns
2Y Excs Rtn is -10%, 3Y Excs Rtn is -54%		 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 26x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 25x
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16%, CFO LTM is 9.0 Bil, FCF LTM is 6.8 Bil		  Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.5%
2 Low stock price volatility
Vol 12M is 22%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.1%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.6%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 16%, CFO LTM is 9.0 Bil, FCF LTM is 6.8 Bil
2 Low stock price volatility
Vol 12M is 22%
3 Weak multi-year price returns
2Y Excs Rtn is -10%, 3Y Excs Rtn is -54%
4 Expensive valuation multiples
P/EBITPrice/EBIT or Price/(Operating Income) ratio is 26x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 25x
5 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -1.5%

Market Valuation & Key Metrics

ABTS&P 500
REVENUE GROWTH 
Rev LTM ($ Bil)43.1
Rev Chg Q7.4%6.1%
Rev Chg LTM5.9%5.2%
Rev Chg 3Y Avg-1.5%5.4%
PROFITABILITYGOOD
Op Inc LTM ($ Bil)7.5
Op Mgn LTM17.4%18.6%
CFO LTM ($ Bil)9.0
CFO/Rev LTM21.0%20.4%
Net Inc LTM ($ Bil)14.0
Net Inc Mgn32.4%12.7%
VALUATIONHIGH
P/S5.23.2
P/CFO24.615.9
P/FCF32.921.0
P/E15.924.2
STABILITYGOOD
Debt/Equity0.060.21
Cash/Assets0.090.07

ABT Stock

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
ABT Return28%31%-21%2%5%15%65%
Peers Return12%15%-13%3%-2%8%23%
S&P 500 Return16%27%-19%24%23%15%106%

Monthly Win Rates [3]
ABT Win Rate67%58%42%50%58%67% 
Peers Win Rate53%50%45%48%52%60% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
ABT Max Drawdown-27%-3%-31%-16%-8%-1% 
Peers Max Drawdown-26%-8%-28%-19%-17%-10% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: JNJ, BSX, MDT, DXCM, BAX. See ABT Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/21/2025 (YTD)

How Low Can It Go

Unique KeyEventABTS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-36.2%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven56.8%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-31.6%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven46.2%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven24 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-11.7%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven13.3%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven50 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-30.6%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven44.1%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1053 days1480 days

Compare to JNJ, BSX, MDT, DXCM, BAX


In The Past

Abbott Laboratories's stock fell -36.2% during the 2022 Inflation Shock from a high on 12/27/2021. A -36.2% loss requires a 56.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Abbott Laboratories (ABT)

Interactive Breakdown

Abbott Laboratories Interactive Breakdown Analysis

Better Bets than Abbott Laboratories (ABT)

 ABTBetter Performance than ABT
MetricValueIndustry (Health Care Equipment)
Rev Chg LTM5.9%ISRG (20.8%), BSX (21.4%), SYK (11.4%), BDX (7.9%), IDXX (6.7%)
Rev Chg 3Y Avg-1.5%ISRG (15.4%), BSX (14.6%), SYK (10.6%), MDT (3.3%), BDX (4.1%)
Op Mgn LTM17.4%ISRG (28.8%), BSX (18.3%), SYK (19.7%), MDT (19.4%), IDXX (31.1%)
CFO/Rev LTM21.0%ISRG (30.9%), BSX (23.2%), IDXX (22.4%), RMD (34.0%), DXCM (23.0%)
FCF/Rev LTM15.7%ISRG (21.8%), BSX (17.5%), SYK (16.9%), IDXX (19.2%), RMD (32.1%)
Total Yield8.1%EW (9.3%), CNMD (9.6%), EMBC (14.2%), UTMD (8.5%), PDEX (10.6%)
 ABTBetter Performance than ABT
MetricValueAll Other Sectors
Rev Chg LTM5.9%NVDA (71.6%), AAPL (6.0%), MSFT (14.9%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg-1.5%NVDA (92.0%), AAPL (1.8%), MSFT (12.5%), GOOGL (10.2%), AMZN (11.3%)
Op Mgn LTM17.4%NVDA (58.1%), AAPL (31.9%), MSFT (45.6%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM21.0%NVDA (46.6%), AAPL (26.6%), MSFT (48.3%), GOOGL (36.0%), META (56.4%)
FCF/Rev LTM15.7%NVDA (43.6%), AAPL (23.5%), MSFT (25.4%), GOOGL (18.0%), META (30.7%)
Total Yield8.1%XOM (9.9%), BABA (37.8%), WFC (9.4%), CVX (9.6%), TM (2071.2%)
 Best Bets In Health Care Sector
 ABTRPRX HALO CPRX LNTH PBH BIIB PFE EW AVTR ILMN
What You Pay           
P/E15.915.614.612.514.614.514.413.110.815.512.4
P/EBIT26.48.211.410.810.09.310.710.626.610.610.3
What You Get           
Rev Chg Q7.4%7.7%40.8%19.4%-4.1%-6.6%6.1%10.3%11.9%-1.1%-4.8%
Rev Chg LTM5.9%3.0%35.0%28.5%5.7%0.6%1.6%13.5%9.1%-2.3%-3.3%
Rev Chg 3Y Avg-1.5%0.8%35.5%49.9%34.3%0.8%-3.1%-12.4%3.0%-4.3%-3.0%
FCF/Rev 3Y Avg14.4%113.4%43.4%38.9%26.1%21.6%16.9%13.8%11.9%9.7%9.0%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Abbott Laboratories Earnings Notes  
2ABT Returns $39 Bil to Shareholders in 10 Years  
3Better Value & Growth: BDX, RMD Top Abbott Laboratories StockActionable 
4How Low Can Abbott Laboratories Stock Really Go?Return 
5Abbott Laboratories vs Microsoft: Which Is A Better Investment?Counter-Intuitive Comparisons 
6Abbott Laboratories vs Eli Lilly: Which Is A Better Investment?Counter-Intuitive Comparisons 
7Abbott Laboratories vs Stryker: Which Is A Better Investment?Counter-Intuitive Comparisons 
8How Does Abbott Laboratories Stock Stack Up Against Its Peers?Peer Comparison 
9Better Bet Than ABT Stock: Pay Less Than Abbott Laboratories To Get More From LLY, COR   
10Better Bet Than ABT Stock: Pay Less Than Abbott Laboratories To Get More From RMD, GMED   
11ARTICLES  
12Pay Less, Grow More: RMD, BDX Outshine Abbott Laboratories Stock October 8th, 2025
13Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From RMD, BDX September 27th, 2025
14Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From RMD, BDX September 9th, 2025
15Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From RMD, BDX August 27th, 2025
16ABT Stock Up 6.4% after 6-Day Win Streak August 9th, 2025
Title
0DASHBOARDS
1Pay Less, Grow More: RMD, BDX Outshine Abbott Laboratories Stock
2Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From RMD, BDX
3Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From RMD, BDX
4Better Bet Than Abbott Laboratories Stock: Pay Less To Get More From RMD, BDX
5ABT Stock Up 6.4% after 6-Day Win Streak
6ARTICLES
7Abbott Laboratories Earnings Notes
8ABT Returns $39 Bil to Shareholders in 10 Years
9Better Value & Growth: BDX, RMD Top Abbott Laboratories Stock
10How Low Can Abbott Laboratories Stock Really Go?
11Abbott Laboratories vs Microsoft: Which Is A Better Investment?
12Abbott Laboratories vs Eli Lilly: Which Is A Better Investment?
13Abbott Laboratories vs Stryker: Which Is A Better Investment?
14How Does Abbott Laboratories Stock Stack Up Against Its Peers?
15Better Bet Than ABT Stock: Pay Less Than Abbott Laboratories To Get More From LLY, COR 
16Better Bet Than ABT Stock: Pay Less Than Abbott Laboratories To Get More From RMD, GMED 

Trade Ideas

Select past ideas related to ABT. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		0.2%0.2%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.6%2.6%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		5.3%5.3%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.1%14.1%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-1.8%-1.8%-8.0%
ABT_9302022_Dip_Buyer_FCFYield09302022ABTAbbott LaboratoriesDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		5.6%2.0%-1.3%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		0.2%0.2%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		2.6%2.6%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		5.3%5.3%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.1%14.1%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-1.8%-1.8%-8.0%
ABT_9302022_Dip_Buyer_FCFYield09302022ABTAbbott LaboratoriesDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		5.6%2.0%-1.3%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1PRAXPraxis Precision Medicines261.8%146.9%
2KODKodiak Sciences52.2%91.0%
3BETRBetter Home & Finance50.0%739.6%
4SIONSionna Therapeutics42.0% 
5CELCCelcuity41.8%400.4%
6CCOClear Channel Outdoor37.0%35.0%
7RAPTRAPT Therapeutics34.1%165.3%
8LBRTLiberty Energy29.8%-18.4%
9PMIPicard Medical29.5%19947.6%
10SANASana Biotechnology28.3%250.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1ASPIASP Isotopes-31.5%112.4%
2LACLithium Americas-30.9%133.7%
3ONDSOndas-30.9%180.9%
4SOCSable Offshore-29.9%-45.9%
5UAMYUnited States Antimony-29.1%600.0%
6USARUSA Rare Earth-28.8%89598.0%
7RGTIRigetti Computing-28.7%162.1%
8AIVApartment Investment & Management-28.7%-7.1%
9RCATRed Cat-28.4%-14.9%
10TMCTMC The Metals-26.9%597.3%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1242.9%351.7%
2QUREuniQure356.0%257.1%
3PRAXPraxis Precision Medicines293.2%146.9%
4LACLithium Americas110.3%133.7%
5NVTSNavitas Semiconductor109.9%321.0%
6CLPTClearPoint Neuro107.6%62.4%
7UAMYUnited States Antimony92.1%600.0%
8GRALGRAIL88.2%369.0%
9TSHATaysha Gene Therapies79.4%197.7%
10SANASana Biotechnology75.7%250.3%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1SOCSable Offshore-47.4%-45.9%
2FLYFirefly Aerospace-43.1% 
3UPWheels Up Experience-40.8%-8.5%
4NFENew Fortress Energy-35.1%-87.5%
5ALABAstera Labs-33.6%18.9%
6VGVenture Global-32.4% 
7GOSSGossamer Bio-31.0%141.0%
8PSIXPower Solutions International-29.3%173.4%
9PGYPagaya Technologies-29.2%214.5%
10USNAUsana Health Sciences-29.2%-41.4%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1PRAXPraxis Precision Medicines261.8%146.9%
2KODKodiak Sciences52.2%91.0%
3BETRBetter Home & Finance50.0%739.6%
4SIONSionna Therapeutics42.0% 
5CELCCelcuity41.8%400.4%
6CCOClear Channel Outdoor37.0%35.0%
7RAPTRAPT Therapeutics34.1%165.3%
8LBRTLiberty Energy29.8%-18.4%
9PMIPicard Medical29.5%19947.6%
10SANASana Biotechnology28.3%250.3%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1ASPIASP Isotopes-31.5%112.4%
2LACLithium Americas-30.9%133.7%
3ONDSOndas-30.9%180.9%
4SOCSable Offshore-29.9%-45.9%
5UAMYUnited States Antimony-29.1%600.0%
6USARUSA Rare Earth-28.8%89598.0%
7RGTIRigetti Computing-28.7%162.1%
8AIVApartment Investment & Management-28.7%-7.1%
9RCATRed Cat-28.4%-14.9%
10TMCTMC The Metals-26.9%597.3%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Abbott Laboratories

Financials

ABTJNJBSXMDTDXCMBAXMedian
NameAbbott L.Johnson .Boston S.MedtronicDexCom Baxter I. 
Mkt Price127.68192.00102.2596.3669.7022.7599.30
Mkt Cap222.6462.0151.3123.527.311.7137.4
Rev LTM43,10990,62718,49434,2004,30110,88726,347
Op Inc LTM7,51522,2283,3886,6476873985,018
FCF LTM6,77516,3973,2345,3035712184,268
FCF 3Y Avg5,97216,9262,1144,9645676583,539
CFO LTM9,03723,0284,2857,1469887655,716
CFO 3Y Avg8,13022,2483,0146,6258841,1664,820

Growth & Margins

ABTJNJBSXMDTDXCMBAXMedian
NameAbbott L.Johnson .Boston S.MedtronicDexCom Baxter I. 
Rev Chg LTM5.9%4.7%21.4%5.0%9.3%3.6%5.4%
Rev Chg 3Y Avg-1.5%4.0%14.6%3.3%17.3%-5.7%3.6%
Rev Chg Q7.4%5.8%22.8%8.4%15.2%4.3%7.9%
QoQ Delta Rev Chg LTM1.8%1.5%5.4%2.0%3.7%1.1%1.9%
Op Mgn LTM17.4%24.5%18.3%19.4%16.0%3.7%17.9%
Op Mgn 3Y Avg16.2%26.3%17.6%18.6%15.8%2.9%16.9%
QoQ Delta Op Mgn LTM0.6%-0.2%-0.2%-0.1%0.7%0.1%0.0%
CFO/Rev LTM21.0%25.4%23.2%20.9%23.0%7.0%22.0%
CFO/Rev 3Y Avg19.6%25.7%18.8%20.2%23.2%11.2%19.9%
FCF/Rev LTM15.7%18.1%17.5%15.5%13.3%2.0%15.6%
FCF/Rev 3Y Avg14.4%19.6%13.1%15.1%14.9%6.3%14.7%

Valuation

ABTJNJBSXMDTDXCMBAXMedian
NameAbbott L.Johnson .Boston S.MedtronicDexCom Baxter I. 
Mkt Cap222.6462.0151.3123.527.311.7137.4
P/S5.25.18.23.66.41.15.1
P/EBIT26.416.445.419.334.0364.630.2
P/E15.920.460.426.547.8-75.323.4
P/CFO24.620.135.317.327.715.322.3
Total Yield8.1%7.5%1.7%6.7%2.1%2.7%4.7%
Dividend Yield1.8%2.6%0.0%2.9%0.0%4.0%2.2%
FCF Yield 3Y Avg3.0%4.5%1.8%4.5%1.4%3.5%3.2%
D/E0.10.10.10.20.10.80.1
Net D/E0.00.10.10.2-0.00.70.1

Returns

ABTJNJBSXMDTDXCMBAXMedian
NameAbbott L.Johnson .Boston S.MedtronicDexCom Baxter I. 
1M Rtn-5.8%8.9%2.1%0.8%3.4%-1.2%1.5%
3M Rtn1.9%15.1%-3.2%5.4%-18.1%-16.7%-0.6%
6M Rtn-2.3%23.6%5.1%16.8%5.2%-19.5%5.1%
12M Rtn11.1%21.6%13.5%8.7%-3.9%-36.4%9.9%
3Y Rtn42.2%24.6%146.2%27.1%-27.1%-56.3%25.9%
1M Excs Rtn-6.9%9.5%2.3%0.7%-0.3%-0.9%0.2%
3M Excs Rtn-4.1%8.4%-13.2%-1.0%-25.2%-25.7%-8.7%
6M Excs Rtn-29.7%-3.8%-22.3%-10.6%-22.2%-46.9%-22.2%
12M Excs Rtn-5.1%5.1%0.3%-5.1%-15.0%-51.8%-5.1%
3Y Excs Rtn-54.0%-60.1%61.9%-58.3%-116.4%-142.7%-59.2%

Comparison Analyses

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date7/30/20254/30/20252/21/202510/31/20247/31/20245/2/20242/16/202411/1/20238/3/20235/4/20232/17/202311/1/2022
Key Financials Quarterly            
Total Revenue11,14210,35810,97410,63510,3779,96410,24110,1439,9789,74710,09110,410
Ebitda3,0482,6652,9732,8832,5522,3822,7672,6612,5952,5212,2812,714
Operating Income2,0521,6931,9111,8591,6691,3861,7801,6471,5421,5091,3041,770
Net Income1,7791,3259,2291,6461,3021,2251,5941,4361,3751,3181,0331,435
EPS1.020.765.330.940.740.700.920.820.790.750.590.82
Key Financials TTM            
Total Revenue TTM43,10942,34441,95041,21740,72540,32640,10939,95940,22641,50543,65345,030
Ebitda TTM11,56911,07310,79010,58410,36210,40510,54410,05810,11110,82212,13113,191
Operating Income TTM7,5157,1326,8256,6946,4826,3556,4786,0026,1256,9598,3629,436
Net Income TTM13,97913,50213,4025,7675,5575,6305,7235,1625,1615,8046,9337,889
Growth Rates Quarterly            
Total Revenue Growth7.4%4.0%7.2%4.9%4.0%2.2%1.5%-2.6%-11.4%-18.1%-12.0%-4.7%
EBITDA Growth19.4%11.9%7.4%8.3%-1.7%-5.5%21.3%-2.0%-21.5%-34.2%-31.7%-21.9%
Operating Income Growth22.9%22.2%7.4%12.9%8.2%-8.2%36.5%-6.9%-35.1%-48.2%-45.2%-30.5%
Net Income Growth36.6%8.2%479.0%14.6%-5.3%-7.1%54.3%0.1%-31.9%-46.1%-48.1%-31.7%
Margins Quarterly            
EBITDA Margin27.4%25.7%27.1%27.1%24.6%23.9%27.0%26.2%26.0%25.9%22.6%26.1%
Operating Income Margin18.4%16.3%17.4%17.5%16.1%13.9%17.4%16.2%15.5%15.5%12.9%17.0%
Net Income Margin16.0%12.8%84.1%15.5%12.5%12.3%15.6%14.2%13.8%13.5%10.2%13.8%
Cash & Debt            
Total Cash7,2826,8447,9677,7887,2196,6517,2797,0478,1559,53210,1709,907
Total Debt13,43713,24215,02114,97914,75414,58615,62815,52816,84616,90017,71616,414
Net Debt / (Cash)6,1556,3987,0547,1917,5357,9358,3498,4818,6917,3687,5466,507
Cash Flows Quarterly            
FCF from Operations2,0471,4172,8682,7051,9601,0253,0381,8771,2031,1432,3262,780
Cash Flows TTM            
FCF from Operations TTM9,0378,9508,5588,7287,9007,1437,2616,5497,4528,6599,58110,322
Returns to Shareholders Quarterly            
Dividends1,0291,026958960961957888888890890823826
Share Repurchases628031575132262592426540685798
Return on Invested Capital (ROIC) Quarterly            
ROIC110.3%78.9%108.4%87.7%71.8%59.6%75.7%66.8%59.6%69.1%54.1%88.8%
Return on Invested Capital (ROIC) TTM            
ROIC TTM122.1%111.5%96.8%79.2%73.4%69.0%66.6%59.0%58.0%78.4%92.5%122.8%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Medical Devices16,88714,80214,48511,78712,239
Diagnostics9,98816,46915,52610,8057,713
Nutritionals8,1547,4598,2947,6477,409
Established Pharmaceutical5,0664,9124,7184,3034,486
Other1411526657
Total40,10943,65343,07534,60831,904


Operating Income by Segment
$ Mil20242023202220212020
Medical Devices5,3064,4364,5333,0383,769
Diagnostics2,4336,6406,2373,7251,912
Nutritionals1,3337061,7631,7511,705
Established Pharmaceutical1,2061,049889794904
Total10,27812,83113,4229,3088,290


Assets by Segment
$ Mil20242023202220212020
Goodwill and intangible assets32,494  38,52840,220
Medical Devices9,0297,8447,2616,8936,640
All other8,458  5,0964,637
Cash and investments8,078  7,9695,023
Diagnostics7,7677,9857,6997,6965,235
Nutritionals4,2703,6253,4253,4783,274
Established Pharmaceutical3,1182,8832,7892,8882,858
Total73,21422,33721,17472,54867,887


Price Behavior

ABT Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta0.770.280.050.300.260.43
Up Beta2.491.250.660.250.190.49
Down Beta2.99-0.170.260.510.410.44
Up Capture21%27%-20%12%21%12%
Bmk +ve Days13233574144420
Stock +ve Days12233669138391
Down Capture12%-32%-30%21%19%62%
Bmk -ve Days8192952107330
Stock -ve Days9192857113359

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date9302025
Short Interest: Shares Quantity18,168,908
Short Interest: % Change Since 91520250.5%
Average Daily Volume5,717,866
Days-to-Cover Short Interest3.18
Basic Shares Quantity1,743,437,000
Short % of Basic Shares1.0%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
10/15/2025-2.9%  
7/17/2025-8.5%-4.5%-1.9%
4/16/20252.8%2.9%5.6%
1/22/20250.8%9.1%14.0%
10/16/20241.5%0.1%-0.3%
7/18/2024-4.4%2.5%6.0%
4/17/2024-3.0%-1.5%-4.2%
1/24/2024-2.8%-0.5%4.4%
...
SUMMARY STATS   
# Positive101413
# Negative141011
Median Positive3.0%3.4%5.6%
Median Negative-2.7%-1.6%-2.9%
Max Positive7.8%9.1%14.0%
Max Negative-8.5%-6.7%-8.9%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025730202510-Q 6/30/2025
3312025430202510-Q 3/31/2025
12312024221202510-K 12/31/2024
93020241031202410-Q 9/30/2024
6302024731202410-Q 6/30/2024
3312024502202410-Q 3/31/2024
12312023216202410-K 12/31/2023
93020231101202310-Q 9/30/2023
6302023803202310-Q 6/30/2023
3312023504202310-Q 3/31/2023
12312022217202310-K 12/31/2022
93020221101202210-Q 9/30/2022
6302022802202210-Q 6/30/2022
3312022503202210-Q 3/31/2022
12312021218202210-K 12/31/2021
93020211103202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Boudreau Philip PEVP AND CFO8112025Sell134.555,550746,7586,862,505Form
1Blount Sally E.5022025Sell129.662,600337,1164,415,960Form
2Shroff EricSenior Vice President3042025Sell138.1756277,6524,417,295Form
3Morrone Louis H.EXECUTIVE VICE PRESIDENT1302025Sell127.392,644336,819 Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.